These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 28862886)
61. The evaluation of hepatic fibrosis scores in children with nonalcoholic fatty liver disease. Mansoor S; Yerian L; Kohli R; Xanthakos S; Angulo P; Ling S; Lopez R; Christine CK; Feldstein AE; Alkhouri N Dig Dis Sci; 2015 May; 60(5):1440-7. PubMed ID: 25540086 [TBL] [Abstract][Full Text] [Related]
62. Obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound. Petrović G; Bjelaković G; Benedeto-Stojanov D; Nagorni A; Brzački V; Marković-Živković B Vojnosanit Pregl; 2016 Oct; 73(10):910-20. PubMed ID: 29327896 [TBL] [Abstract][Full Text] [Related]
63. 13C-Methacetin Breath Testing in Patients with Non-Alcoholic Fatty Liver Disease. Kempiński R; Neubauer K; Wieczorek S; Dudkowiak R; Jasińska M; Poniewierka E Adv Clin Exp Med; 2016; 25(1):77-81. PubMed ID: 26935501 [TBL] [Abstract][Full Text] [Related]
64. Metabonomics screening of serum identifies pyroglutamate as a diagnostic biomarker for nonalcoholic steatohepatitis. Qi S; Xu D; Li Q; Xie N; Xia J; Huo Q; Li P; Chen Q; Huang S Clin Chim Acta; 2017 Oct; 473():89-95. PubMed ID: 28842175 [TBL] [Abstract][Full Text] [Related]
65. A novel noninvasive diagnostic method for nonalcoholic steatohepatitis using two glycobiomarkers. Kamada Y; Ono M; Hyogo H; Fujii H; Sumida Y; Mori K; Tanaka S; Yamada M; Akita M; Mizutani K; Fujii H; Yamamoto A; Takamatsu S; Yoshida Y; Itoh Y; Kawada N; Chayama K; Saibara T; Takehara T; Miyoshi E Hepatology; 2015 Nov; 62(5):1433-43. PubMed ID: 26199205 [TBL] [Abstract][Full Text] [Related]
66. Predictive value of neutrophiltolymphocyte ratio in the severity of non-alcoholic fatty liver disease among type 2 diabetes patients. Kahraman NK; Kahraman C; Koçak FE; Coşgun S; Şanal B; Korkmaz M; Bayhan Z; Zeren S Acta Gastroenterol Belg; 2016; 79(3):295-300. PubMed ID: 27821024 [TBL] [Abstract][Full Text] [Related]
67. Tissue Inhibitors of Metalloproteinase-1 and 2 and Obesity Related Non-Alcoholic Fatty Liver Disease: Is There a Relationship. Abdelaziz R; Elbasel M; Esmat S; Essam K; Abdelaaty S Digestion; 2015; 92(3):130-7. PubMed ID: 26329758 [TBL] [Abstract][Full Text] [Related]
68. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. Kargiotis K; Athyros VG; Giouleme O; Katsiki N; Katsiki E; Anagnostis P; Boutari C; Doumas M; Karagiannis A; Mikhailidis DP World J Gastroenterol; 2015 Jul; 21(25):7860-8. PubMed ID: 26167086 [TBL] [Abstract][Full Text] [Related]
69. Metabolomics for genomics: the role of vitamin D in nonalcoholic fatty liver disease. Crisan D; Radu C; Suciu A; Grigorescu MD; Stefanescu H; Romanciuc F; Socaciu C; Grigorescu M J Gastrointestin Liver Dis; 2015 Sep; 24(3):394-5. PubMed ID: 26405717 [No Abstract] [Full Text] [Related]
70. Clinical relevance of liver histopathology and different histological classifications of NASH in adults. Nascimbeni F; Ballestri S; Machado MV; Mantovani A; Cortez-Pinto H; Targher G; Lonardo A Expert Rev Gastroenterol Hepatol; 2018 Apr; 12(4):351-367. PubMed ID: 29224471 [TBL] [Abstract][Full Text] [Related]
71. Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference. Poynard T; Munteanu M; Charlotte F; Perazzo H; Ngo Y; Deckmyn O; Pais R; Merrouche W; de Ledinghen V; Mathurin P; Ratziu V; Eur J Gastroenterol Hepatol; 2018 May; 30(5):569-577. PubMed ID: 29406435 [TBL] [Abstract][Full Text] [Related]
72. [[113th Scientific Meeting of the Japanese Society of Internal Medicine: Educational Lecture: Diagnosis and Management of Non-alcoholic Fatty Liver Diseases and Non-alcoholic Steatohepatitis: Current Concepts]. Hashimoto E Nihon Naika Gakkai Zasshi; 2016 Sep; 105(9):1753-60. PubMed ID: 30169948 [No Abstract] [Full Text] [Related]
73. Commonalities and Distinctions Between Alcoholic and Nonalcoholic Fatty Liver Disease. Sanyal AJ; Mathurin P; Nagy LA Gastroenterology; 2016 Jun; 150(8):1695-7. PubMed ID: 27155520 [No Abstract] [Full Text] [Related]
74. Treatment of NASH: What Helps Beyond Weight Loss? Banini BA; Sanyal AJ Am J Gastroenterol; 2017 Jun; 112(6):821-824. PubMed ID: 28397875 [No Abstract] [Full Text] [Related]
75. Relationship between psoriasis and non-alcoholic fatty liver disease - Updated systematic review and adjusted meta-analysis. Phan K; Onggo J; Charlton O; Smith SD Australas J Dermatol; 2019 Nov; 60(4):e352-e355. PubMed ID: 30906989 [No Abstract] [Full Text] [Related]
76. Letter to the editor: Serum thrombospondin-2 as biomarker in liver diseases, a look beyond NASH. Colasanti T; Di Giamberardino A; Grimaldi A; Cardinale V; Carpino G; Mancone C Hepatology; 2022 Apr; 75(4):1056-1057. PubMed ID: 34927752 [No Abstract] [Full Text] [Related]